Comparative Pharmacology
Head-to-head clinical analysis: PULMICORT FLEXHALER versus SECREFLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PULMICORT FLEXHALER versus SECREFLO.
PULMICORT FLEXHALER vs SECREFLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Budesonide is a corticosteroid with potent anti-inflammatory effects. It inhibits multiple inflammatory cell types and mediators such as cytokines, chemokines, and adhesion molecules, reducing airway hyperresponsiveness and inflammation.
SecReFlo is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity by inhibiting presynaptic serotonin reuptake.
Inhalation: 1-2 inhalations (90-180 mcg) twice daily; maximum 720 mcg twice daily.
One inhalation (200 mcg albuterol sulfate/80 mcg ipratropium bromide) orally 4 times daily via metered-dose inhaler. May increase to 2 inhalations 4 times daily if needed.
None Documented
None Documented
Terminal half-life: 2.0-3.5 hours (mean 2.5 h) in adults after inhalation. Clinically, duration of effect may persist beyond pharmacokinetic half-life due to receptor binding.
Terminal elimination half-life is 2.5 hours in patients with normal renal function. In moderate renal impairment (CrCl 30-50 mL/min), half-life increases to 4.5 hours; in severe impairment (<30 mL/min), half-life is 8 hours, requiring dosage adjustment.
Renal: ~60% as metabolites, fecal: ~40% as metabolites. Less than 10% unchanged in urine.
Renal: 75% as unchanged drug; fecal: 20%; biliary: 5%. Total clearance is 0.8 L/h/kg, with renal clearance accounting for 0.6 L/h/kg, indicating active tubular secretion.
Category C
Category C
Inhaled Corticosteroid
Inhaled Corticosteroid/Long-acting Beta Agonist